Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL28041858 | 0.90 | DPP4 (0.50) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL27837499 | 0.86 | DPP4 (0.47) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL2783498 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL8868 | 0.85 | — | — | |
| Isoleucine SCHEMBL5973421 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL1147268 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL8045737 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL1255583 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL8043620 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL8186739 | 0.85 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | DPP4 1/4885DPP8 8/4885DPP9 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.